NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Price as of Jan 6, 2025
ZURICH and NESS ZIONA, Israel, Jan. 8, 2025 /PRNewswire/ — NLS Pharmaceutics Ltd. (“NLS”) (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kad
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Price as of Jan 6, 2025
ZURICH and NESS ZIONA, Israel, Jan. 8, 2025 /PRNewswire/ — NLS Pharmaceutics Ltd. (“NLS”) (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kad
Abzena Strengthens Board with Appointment of Biopharma Industry Leader, Dr Moncef Slaoui
SAN DIEGO, Jan. 8, 2025 /PRNewswire/ — Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has today announced the appointment of Dr Moncef Slaoui, PhD, to its Board of Directors. A highly accomplished leader in the biopharmaceutical industry with ove
Natural Grocers® Opens Its Doors in Brownsville, TX With a Grand Opening Celebration on January 22, 2025
Customers will enjoy unbeatable savings, exciting giveaways, sweepstakes, delicious samples and more LAKEWOOD, Colo., Jan. 8, 2025 /PRNewswire/ — Natural Grocers®, the leading family-operated organic and natural grocery retailer in the U.S., is thrilled to announce the opening of its newest s
Natural Grocers® Expands Private-Label Line with Six New Household-Cleaning Products
LAKEWOOD, Colo., Jan. 8, 2025 /PRNewswire/ — Looking for a fresh start to the new year? Why not begin with a cleaner, healthier home? Natural Grocers®, America’s largest family-operated organic and natural grocery retailer, is here to help with six exciting new additions to its private-
BIZCLIK MEDIA LAUNCHES JANUARY EDITIONS OF FINTECH MAGAZINE & INSURTECH DIGITAL
The January editions of FinTech Magazine and InsurTech Digital contains exclusive insights from EY, Hiscox & Storebrand. LONDON, Jan. 8, 2025 /PRNewswire/ — BizClik, the UK’s fastest-growing publishing company, has published the latest editions of FinTech Magazine and InsurTech Dig
7-Eleven Rewards Customers with the Chance to Win $5,000 Every. Single. Day. in 2025
Score a chance to win $5,000 daily when shopping with 7Rewards and Speedy Rewards, only at 7-Eleven and Speedway IRVING, Texas, Jan. 8, 2025 /PRNewswire/ — Today, 7-Eleven, Inc., announced that it is rewarding loyal customers with the opportunity to win big like never before – every single d
Park Signalling wins £3m contract with Network Rail to produce SSI design workstation
OXFORD, England, Jan. 8, 2025 /PRNewswire/ — Park Signalling, a Unipart company, has won a £3m contract with Network Rail to produce a Design Workstation that will support Solid State Interlocking (SSI) signalling systems in the UK. Configuring SSI systems requires specialised knowledge of r
Discover Sungrow’s Advanced Solar Solutions at WFES 2025
Event Highlights New Product Launch: Witness the unveiling of Sungrow’s next-generation string inverter, designed specifically for commercial and industrial (C&I) applications in the MENA region. Innovative Product Showcase: Explore Sungrow’s diverse solutions and 30+ products, inc
Published in Annals of Oncology: Disitamab Vedotin Combined with PD-1 Inhibitor is a Promising Treatment for Locally Advanced or Metastatic Urothelial Carcinoma
YANTAI, China, Jan. 8, 2025 /PRNewswire/ — On Janurary 7th, 2025, Annals of Oncology (IF: 56.7), a top oncology journal globally, published remarkable long-term follow-up results of a phase 1b/2 clinical trial on Disitamab Vedotin (DV) (developed by Remegen Co., Ltd) combined with Toripalima
